Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients

Breast Cancer Research and Treatment

Volumn 142, Issue 3, 2013, Pages 559-567

  Ko, Kyung Lan ^a   Shin, In Suk ^a   You, Ji Young ^a   Jung, So Youn ^a   Ro, Jungsil ^a   Lee, Eun Sook ^a  

^a National Cancer Center   (South Korea)

Author keywords

Adjuvant tamoxifen therapy; Breast cancer; Estrogen receptor positive; Mammographic breast density

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; CONTROLLED STUDY; DRUG RESPONSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PREDICTION; PREMENOPAUSE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; TAMOXIFEN-INDUCED MAMMOGRAPHIC BREAST DENSITY REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPHATIC METASTASIS; MAMMARY GLANDS, HUMAN; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PREMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TAMOXIFEN; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84890310014     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2726-4     Document Type: Article

References (19)

1. Jensen EV, Jordan VC (2003) The estrogen receptor: a model for molecular medicine. Clin Cancer Res 9(6):1980-1989
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687-1717. doi: 10.1016/S0140-6736(05)66544-0
3. Prowell TM, Blackford AL, Byrne C, Khouri NF, Dowsett M, Folkerd E, Tarpinian KS, Powers PP, Wright LA, Donehower MG, Jeter SC, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Garrett-Mayer E, Skaar TC, Davidson NE, Stearns V, et al. (2011) Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila) 4(12):1993-2001. doi: 10.1158/1940-6207.capr-11-0154
4. Johns PC, Yaffe MJ (1987) X-ray characterisation of normal and neoplastic breast tissues. Phys Med Biol 32(6):675-695
5. Boyd NF, Martin LJ, Yaffe MJ, Minkin S (2006) Mammographic density: a hormonally responsive risk factor for breast cancer. J Br Menopause Soc 12(4):186-193. doi: 10.1258/136218006779160436
6. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ (2007) Mammographic density and the risk and detection of breast cancer. New Engl J Med 356(3):227-236. doi: 10.1056/NEJMoa062790
7. Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M, Siozon CC, Pike MC (2003) Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 12(4):332-338
8. Nagata C, Matsubara T, Fujita H, Nagao Y, Shibuya C, Kashiki Y, Shimizu H (2005) Mammographic density and the risk of breast cancer in Japanese women. Br J Cancer 92(12):2102-2106. doi: 10.1038/sj.bjc.6602643
9. Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM (2011) Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 103(9):744-752. doi: 10.1093/jnci/djr079
10. Kim J, Han W, Moon HG, Ahn SK, Shin HC, You JM, Han SW, Im SA, Kim TY, Koo HR, Chang JM, Cho N, Moon WK, Noh DY (2012) Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res 14(4):R102. doi: 10.1186/bcr3221
11. Bartlett JM, Bloom KJ, Piper T, Lawton TJ, van de Velde CJ, Ross DT, Ring BZ, Seitz RS, Beck RA, Hasenburg A, Kieback D, Putter H, Markopoulos C, Dirix L, Seynaeve C, Rea D (2012) Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. J Clin Oncol. doi: 10.1200/jco.2012.42.8896
12. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631-643. doi: 10.1038/nrc2713
13. Vachon CM, Brandt KR, Ghosh K, Scott CG, Maloney SD, Carston MJ, Pankratz VS, Sellers TA (2007) Mammographic breast density as a general marker of breast cancer risk. Cancer Epidemiol Biomarkers Prev 16(1):43-49. doi: 10.1158/1055-9965.epi-06-0738
14. Jeon JH, Kang JH, Kim Y, Lee HY, Choi KS, Jun JK, Oh DK, Lee CY, Ko K, Park EC (2011) Reproductive and hormonal factors associated with fatty or dense breast patterns among Korean women. Cancer Res Treat 43(1):42-48. doi: 10.4143/crt.2011.43.1.42
15. Verheus M, Maskarinec G, Erber E, Steude JS, Killeen J, Hernandez BY, Cline JM (2009) Mammographic density and epithelial histopathologic markers. BMC Cancer 9:182. doi: 10.1186/1471-2407-9-182
16. Ghosh K, Brandt KR, Reynolds C, Scott CG, Pankratz VS, Riehle DL, Lingle WL, Odogwu T, Radisky DC, Visscher DW, Ingle JN, Hartmann LC, Vachon CM (2012) Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Res Treat 131(1):267-275. doi: 10.1007/s10549-011-1727-4
17. Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14(5):1718-1729
18. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C (2005) Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 104(8):1575-1579. doi: 10.1002/cncr.21385
19. Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S (2010) Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst 102(16):1224-1237. doi: 10.1093/jnci/djq239